Ovarian Cancer

Avastin Plus ChemoTx Approved for Advanced Ovarian Cancer After Resection

By June 13, 2018

Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).

Rubraca Approved as Maintenance Treatment for Recurrent Ovarian Cancer

By April 06, 2018

The new approval was based on data from the Phase 3 ARIEL3 clinical trial (N=564).

FDA Approves New Indication, Formulation for Lynparza

By August 18, 2017

The approvals were based on two, placebo-controlled trials (SOLO-2, Study 19) in patients with recurrent ovarian cancers who were in response to platinum-based therapy.